SG11201600706PA - In vitro method for determining the stability of compositions comprising soluble fc gamma receptor(s) - Google Patents

In vitro method for determining the stability of compositions comprising soluble fc gamma receptor(s)

Info

Publication number
SG11201600706PA
SG11201600706PA SG11201600706PA SG11201600706PA SG11201600706PA SG 11201600706P A SG11201600706P A SG 11201600706PA SG 11201600706P A SG11201600706P A SG 11201600706PA SG 11201600706P A SG11201600706P A SG 11201600706PA SG 11201600706P A SG11201600706P A SG 11201600706PA
Authority
SG
Singapore
Prior art keywords
soluble
compositions
stability
determining
vitro method
Prior art date
Application number
SG11201600706PA
Inventor
Peter Sondermann
Thomas Pohl
Meer Dominik Ter
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of SG11201600706PA publication Critical patent/SG11201600706PA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201600706PA 2013-08-01 2014-08-01 In vitro method for determining the stability of compositions comprising soluble fc gamma receptor(s) SG11201600706PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13003835.9A EP2833139A1 (en) 2013-08-01 2013-08-01 In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s)
PCT/EP2014/066646 WO2015015001A1 (en) 2013-08-01 2014-08-01 In vitro method for determining the stability of compositions comprising soluble fc gamma receptor(s)

Publications (1)

Publication Number Publication Date
SG11201600706PA true SG11201600706PA (en) 2016-02-26

Family

ID=48917312

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201600706PA SG11201600706PA (en) 2013-08-01 2014-08-01 In vitro method for determining the stability of compositions comprising soluble fc gamma receptor(s)

Country Status (14)

Country Link
US (1) US10866247B2 (en)
EP (2) EP2833139A1 (en)
JP (2) JP6697385B2 (en)
KR (1) KR102282823B1 (en)
CN (1) CN105593685B (en)
AU (1) AU2014298371B2 (en)
BR (1) BR112016001898A2 (en)
CA (1) CA2919997C (en)
EA (1) EA030087B1 (en)
ES (1) ES2687716T3 (en)
IL (1) IL243861B (en)
MX (1) MX370732B (en)
SG (1) SG11201600706PA (en)
WO (1) WO2015015001A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2833139A1 (en) 2013-08-01 2015-02-04 SuppreMol GmbH In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (en) 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmaceutical composition containing sFcRgamma IIb or sFcRgamma III
EP1664119A1 (en) * 2003-09-08 2006-06-07 Medical Research Council Method for the treatment or prophylaxis of tuberculosis
US8354109B2 (en) * 2005-12-13 2013-01-15 Suppremol Gmbh Multimeric Fc receptor polypeptides
US20090156422A1 (en) * 2006-06-02 2009-06-18 Koninklijke Philips Electronics N.V. Device and method to detect analytes
EP1870422A1 (en) * 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
ES2582581T3 (en) 2009-09-29 2016-09-13 F. Hoffmann-La Roche Ag Prefiltration adjustment of solute buffer for the preparation of high concentration immunoglobulins
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
EA201300524A1 (en) * 2010-11-01 2013-08-30 ДСМ АйПи АССЕТС Б.В. CLEANING ANTIBODIES BY ION-EXCHANGE CHROMATOGRAPHY IN A SINGLE BLOCK
CN103105326A (en) * 2012-12-30 2013-05-15 上海市内分泌代谢病研究所 Method for surface staining and intracellular staining of Th cells and application of method
EP2833139A1 (en) 2013-08-01 2015-02-04 SuppreMol GmbH In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s)

Also Published As

Publication number Publication date
EA030087B1 (en) 2018-06-29
EA201690319A1 (en) 2016-06-30
US10866247B2 (en) 2020-12-15
AU2014298371A1 (en) 2016-02-18
KR102282823B1 (en) 2021-07-29
EP2833139A1 (en) 2015-02-04
EP3028041B1 (en) 2018-07-18
MX2016001288A (en) 2016-07-07
KR20160036058A (en) 2016-04-01
CN105593685A (en) 2016-05-18
CN105593685B (en) 2017-11-24
CA2919997C (en) 2021-11-02
BR112016001898A2 (en) 2017-09-05
IL243861A0 (en) 2016-04-21
JP6697385B2 (en) 2020-05-20
ES2687716T3 (en) 2018-10-26
EP3028041A1 (en) 2016-06-08
CA2919997A1 (en) 2015-02-05
IL243861B (en) 2019-06-30
JP2016525364A (en) 2016-08-25
AU2014298371B2 (en) 2020-05-07
WO2015015001A1 (en) 2015-02-05
US20160195541A1 (en) 2016-07-07
MX370732B (en) 2019-12-20
JP2020000244A (en) 2020-01-09

Similar Documents

Publication Publication Date Title
IL289821B (en) Compositions and methods for immunotherapy
ZA202003200B (en) Compositions, methods, and systems for the synthesis and use of imaging agents
HK1220387A1 (en) Compositions and methods for immunotherapy
HK1207316A1 (en) Anti-prolactin receptor antibody formulations
EP3019057A4 (en) Portafilter and grounds weighing platform system and methods of use
IL285527A (en) Compositions and methods for immunotherapy
EP3057616A4 (en) Buffer formulations for enhanced antibody stability
EP2983789A4 (en) Compositions and methods for the delivery of therapeutics
HRP20171016T8 (en) Highly concentrated formulations of soluble fc gamma receptors
IL243861B (en) In vitro method for determining the stability of compositions comprising soluble fc gamma receptors
EP3046468A4 (en) Methods and compositions for imaging disorders using polyspecific agents
AP3759A (en) Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same
ZA201300163B (en) Improved pharmaceutical composition containing an aldosterone antagonist and method for the preparation thereof